Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

The Swiss company was evaluating tiragolumab with its blockbuster PD-L1 inhibitor Tecentriq (atezolizumab ... positive Phase II data for its PD-1 inhibitor Jemperli (dostarlimab) and the ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a ... an FDA breakthrough designation for its PD-L1 inhibitor Tecentriq (atezolizumab) in combination with VEGF inhibitor ...

Casdozokitug, combined with atezolizumab and bevacizumab, shows durable responses and a 17.2% complete response rate in HCC ...

demonstrated improved outcomes for SCLC patients when lurbinectedin was combined with the PD-L1 inhibitor atezolizumab (Tecentriq). "These promising results provide further validation for the ...

Researchers aim to validate the AI tool SCORPIO in prospective studies and eventually seek FDA clearance to sell it as a commercial tool in the US.

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells." ...